Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist by Poole Aleksandra Jovanovic, Li Ying, Kim Yoon, Lin Suh-Chin J, Lee Wen-Hwa, Lee Eva Y-H P in Science (New York, N.Y.) (2006). PubMed


Women with mutations in the breast cancer susceptibility gene BRCA1 are predisposed to breast and ovarian cancers. Why the BRCA1 protein suppresses tumor development specifically in ovarian hormone-sensitive tissues remains unclear. We demonstrate that mammary glands of nulliparous Brca1/p53-deficient mice accumulate lateral branches and undergo extensive alveologenesis, a phenotype that occurs only during pregnancy in wild-type mice. Progesterone receptors, but not estrogen receptors, are overexpressed in the mutant mammary epithelial cells because of a defect in their degradation by the proteasome pathway. Treatment of Brca1/p53-deficient mice with the progesterone antagonist mifepristone (RU 486) prevented mammary tumorigenesis. These findings reveal a tissue-specific function for the BRCA1 protein and raise the possibility that antiprogesterone treatment may be useful for breast cancer prevention in individuals with BRCA1 mutations.

[ hide abstract ]

Discussed In Paper


Dosing Information

No dosing information annotated.